Cutaneous metastases from prostate cancer revealing neuroendocrine differentiation

Affiliations

¹ Department of Dermatology, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
² Department of Pathology, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Case Reports

Mónica Munera-Campos et al. J Cutan Pathol. 2019 Dec.

. 2019 Dec;46(12):976-978.

doi: 10.1111/cup.13561. Epub 2019 Aug 27.

¹ Department of Dermatology, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
² Department of Pathology, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

No abstract available

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30. https://doi.org/10.3322/caac.21442.
1. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501-5511. https://doi.org/10.1038/onc.2013.206.
1. Dicken H, Hensley PJ, Kyprianou N. Prostate tumor neuroendocrine differentiation via EMT: the road less traveled. Asian J Urol. 2019;6:82-90. https://doi.org/10.1016/j.ajur.2018.11.001.
1. Sainio M, Visakorpi T, Tolonen T, Ilvesaro J, Bova GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol Res Pract. 2018;214:848-856. https://doi.org/10.1016/j.prp.2018.04.015.
1. Li Z, Chen CJ, Wang JK, et al. Neuroendocrine differentiation of prostate cancer. Asian J Androl. 2013;15:328-332. https://doi.org/10.1038/aja.2013.7.